CHICAGO: Anglo-Swedish drugmaker AstraZeneca has released 'encouraging' early research data for Tagrisso (osimertinib) in patients with leptomeningeal (LM) disease at the American Society of Clinical Oncology (ASCO) annual meeting.
LM is a complication of epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC), where cancer cells spread to the cerebrospinal fluid (CSF).
The updated BLOOM Phase I data, presented at ASCO on Monday, reveals that irrespective of T790M status of patients, osimertinib led to a change in MRI signal intensity, which is indicative of a reduction in central nervous system (CNS) lesions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze